ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.139,20
0,72%
S&P 500
6.049,88
0,05%
US Dollar vs BRL
6,0413
-0,05%
Bitcoin
96.779,45
0,83%
Brent Oil
73,66
0,07%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Acumen Pharmaceuticals Inc (ABOS)

  7. Acumen Pharmaceuticals Inc (ABOS) Notícias

ABOS

Acumen Pharmaceuticals (ABOS)

Acumen Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABOS
DataHoraFonteTítuloCódigoCompanhia
26/11/202418:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202418:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABOSAcumen Pharmaceuticals Inc
12/11/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
11/11/202418:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202419:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202419:24Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202418:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/11/202410:00GlobeNewswire Inc.Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNASDAQ:ABOSAcumen Pharmaceuticals Inc
05/11/202418:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
31/10/202409:05GlobeNewswire Inc.Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
23/10/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
30/09/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/09/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
25/09/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
03/09/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202408:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/08/202408:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
06/08/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
29/07/202408:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
28/07/202408:30GlobeNewswire Inc.Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
14/05/202408:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
13/05/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202418:47GlobeNewswire Inc.Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare ConferenceNASDAQ:ABOSAcumen Pharmaceuticals Inc
08/05/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
07/05/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
16/04/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
04/04/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s DiseaseNASDAQ:ABOSAcumen Pharmaceuticals Inc
26/03/202408:00GlobeNewswire Inc.Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business HighlightsNASDAQ:ABOSAcumen Pharmaceuticals Inc
21/03/202409:00GlobeNewswire Inc.Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual MeetingNASDAQ:ABOSAcumen Pharmaceuticals Inc
19/03/202417:00GlobeNewswire Inc.Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024NASDAQ:ABOSAcumen Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ABOS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BOBR4
BOMBRIL PN
BOV
IFCM3
Infracommerce Caxaas ON
BOV
ATOM3
ATOMPAR ON
BOV
OIBR3
OI ON
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
PFRM3
PROFARMA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados